J.B. Chemicals & Pharmaceuticals DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.74×	0.74×
	1.03×	1.03×	0.99×	0.96×
	22.3%	22.0%	21.8%	18.5%
	0.90×	0.95×	0.92×	1.02×
	1.19×	1.24×	1.37×	1.43×
	18.4%	19.9%	19.9%	19.0%
	18.7%	20.8%	20.5%	17.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

JBCHEPHARM

J.B. Chemicals & Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersTORNTPHARM ALKEM IPCALAB SAILIFE NH NEULANDLAB ACUTAAS NATCOPHARM

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.74	0.74	0.74	0.74
Interest Burden (Pretax/EBIT) ×	0.96	0.99	1.03	1.03
EBIT Margin %	18.46	21.77	21.97	22.30
Asset Turnover ×	1.02	0.92	0.95	0.90
Financial Leverage (Assets/Equity) ×	1.43	1.37	1.24	1.19
ROE (5-step product, year-end total equity) %	19.03	19.94	19.91	18.39
ROE (owners' profit / average owners' equity) %	17.76	20.45	20.75	18.69

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.